Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host 1x1 investor meetings at the Stifel 2024 Healthcare Conference.
马萨诸塞州剑桥，2024年11月12日（GLOBE NEWSWIRE）——临床阶段的细胞和基因组工程公司Vor Bio（纳斯达克股票代码：VOR）今天宣布，它将在Stifel 2024医疗保健会议上参加炉边谈话并主办1x1投资者会议。
Stifel 2024 Healthcare Conference
Fireside Chat: Monday, November 18, 2024 at 2:25 pm ET
Location: New York, NY
Stifel 2024 年医疗保健会议
炉边谈话：美国东部时间 2024 年 11 月 18 日星期一下午 2:25
地点：纽约州纽约
A live webcast and archived replay of the fireside chat will be available on the investors section of .
的投资者专区将提供炉边谈话的网络直播和存档重播。
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .
关于 Vor Bio
Vor Bio是一家临床阶段的细胞和基因组工程公司，旨在通过设计造血干细胞来实现移植后的靶向治疗，从而改变血液癌患者的护理标准。欲了解更多信息，请访问：。
Contact:
联系人：
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
媒体与投资者
莎拉·斯宾塞
+1 857-242-6076
sspencer@vorbio.com
